MEGAVAC-P Inact

Indications

• Dyspepsia
• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Heartburn
• Diarrhea
• Mucosal irritations

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated.

Mechanism of action

Aluminum acts as an astringent, causing local shrinkage or constriction of body tissues through osmotic flow of fluids away from the area of application. This mechanism assists in reducing mucous secretions and managing conditions such as peptic ulcers and diarrhea. Additionally, it can help in drying and hardening of tissues when applied topically.

Pharmacodynamics

Aluminum-based antacids work by neutralizing gastric acid, leading to an increase in gastric pH. This action helps to alleviate symptoms associated with excess gastric acid, such as heartburn and discomfort. The astringent properties of aluminum also contribute to its therapeutic effects in managing mucosal irritations and secretions.

Pharmacokinetics

Aluminum is absorbed minimally when taken orally, with a bioavailability of about 0.1 to 0.5%. The majority of aluminum is excreted renally, and its half-life can be prolonged in individuals with renal impairment. Long-term use may lead to accumulation and potential toxicity, particularly impacting bone and neurological health.

Interactions

• aluminiumhydroxide+deferasirox: Severe (decreases exposure)
• aluminiumhydroxide+enteralfeeds: Unknown (increases risk of blocked enteral or nasogastric tubes)
• aluminiumhydroxide+roxadustat: Unknown (decreases exposure)

Pregnancy

Aluminum compounds are generally considered safe in pregnancy when used as directed. However, excessive exposure should be avoided.

Breast-feeding

Aluminum is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• aluminium hydroxide suspension
• aluminium hydroxide tablets

Indications

• Vaccination against infectious diseases
• Allergy testing and immunotherapy
• Monoclonal antibody production
• Transplantation to prevent organ rejection

Dosage

Children: Dosing of antigens in children also depends on the specific antigen and the clinical indication. For pediatric vaccinations, refer to the BNF for Children.

Adults: Dosing of antigens is highly variable and depends on the specific antigen and the clinical indication. For vaccine administration, refer to national immunization guidelines.

Mechanism of action

Antigens work by binding to specific receptors on the surface of immune cells, such as B cells and T cells. This binding triggers a cascade of immune responses, including the proliferation of specific immune cell populations and the production of antibodies that target the antigen. This process is crucial for the development of adaptive immunity, allowing the body to remember and respond more effectively to future encounters with the same antigen.

Pharmacodynamics

The pharmacodynamics of antigens involve the interaction with the immune system to elicit a response. The magnitude and quality of this response can vary based on several factors, including the nature of the antigen, the route of exposure, and the host's immune status. Antigens can be classified as T-cell dependent or T-cell independent, influencing the type of immune response generated.

Pharmacokinetics

Antigens are processed by antigen-presenting cells (APCs) that present peptide fragments to T cells. The pharmacokinetics of antigens can vary widely depending on their form (e.g., live attenuated, inactivated, or subunit vaccines). Generally, once introduced into the body, antigens are taken up by APCs, which then migrate to lymph nodes to activate T and B cells. The duration of immune response can be influenced by the type of antigen and the presence of adjuvants.

Pregnancy

Safety during pregnancy depends on the specific type of antigen. Consult relevant guidelines for specific antigens.

Breast-feeding

Safety during breastfeeding varies by antigen type. Consult relevant guidelines for specific antigens.

Storage

Store at controlled room temperature, away from light and moisture. Specific storage conditions may vary based on the type of antigen.

Indications

• pH stabilization in laboratory experiments
• buffering during physiological studies
• preparation of samples for biochemical assays
• maintenance of pH in parenteral fluids

Dosage

Children: Refer to specific buffer formulations for detailed dosing guidance.

Adults: Refer to specific buffer formulations for detailed dosing guidance.

Mechanism of action

Buffers work by neutralizing added acids or bases through chemical reactions. For example, a buffer composed of acetic acid and sodium acetate can absorb excess hydrogen ions (from added acids) or donate hydrogen ions (to neutralize added bases), thus stabilizing the pH of the solution. This equilibrium is governed by the Henderson-Hasselbalch equation, which relates pH to the concentrations of the acidic and basic components of the buffer.

Pharmacodynamics

The pharmacodynamics of buffers involves their capacity to maintain pH levels within a target range, which is essential for various physiological processes. For instance, physiological buffers such as bicarbonate and phosphate play critical roles in maintaining the acid-base balance in the body, ensuring proper cellular function, enzyme activity, and metabolic processes.

Pharmacokinetics

The pharmacokinetics of buffer components depends on their specific chemical nature. Weak acids and bases used in buffers are typically absorbed and metabolized according to their molecular characteristics. For instance, bicarbonate can be reabsorbed in the kidneys and plays a significant role in systemic pH regulation. However, since buffer solutions are not typically absorbed in the same way as pharmaceutical drugs, their pharmacokinetic profiles are less relevant in a conventional sense.

Pregnancy

Buffering agents are generally considered safe during pregnancy; however, specific formulations should be evaluated for safety and efficacy.

Breast-feeding

Most buffering agents are considered safe during breastfeeding, but it is advisable to consult healthcare providers regarding specific formulations.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Follow specific storage instructions on the product label.

Indications

• Pain management
• Inflammation
• Infections
• Chronic diseases
• Allergic reactions

Dosage

Children: Dosage for paediatric canines (puppies) also varies widely depending on the specific medication, age, and weight of the puppy. Veterinary guidance is crucial for determining appropriate doses.

Adults: Dosage for adult canines varies based on the specific medication and condition being treated. It is essential to consult veterinary guidelines or a veterinarian for appropriate dosing.

Mechanism of action

The mechanism of action of canine medications varies widely depending on the specific drug class. For example, non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Antibiotics may work by inhibiting bacterial cell wall synthesis or protein synthesis, while corticosteroids reduce inflammation by inhibiting immune response.

Pharmacodynamics

Pharmacodynamics in canines involves understanding how drugs affect the body, including their therapeutic effects and potential side effects. For example, NSAIDs provide analgesic and anti-inflammatory effects, while antibiotics target specific pathogens to eliminate infections. The response to drugs can vary based on factors such as breed, age, and overall health status.

Pharmacokinetics

Pharmacokinetics in canine patients encompasses the absorption, distribution, metabolism, and excretion of drugs. Canine physiology can influence these processes; for example, drugs may be absorbed more quickly in dogs due to differences in gastrointestinal pH and transit time. Metabolism often occurs in the liver, with variations based on breed and age affecting drug clearance. Excretion primarily takes place through the kidneys.

Pregnancy

Safety during pregnancy has not been established. Consult a veterinarian for guidance.

Breast-feeding

Safety during lactation has not been established. Consult a veterinarian for guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific guidelines for pediatric dosing; consult the BNF for Children for accurate dosage information.

Adults: Refer to specific guidelines for use; dosage may vary based on the context of use.

Mechanism of action

Hydroxide ions act primarily as bases, neutralizing acids to form water and salts. They participate in various biochemical pathways, including selenium metabolism and the degradation of reactive oxygen species. Hydroxide can influence enzyme activity and stability by altering the pH of the environment, thereby affecting metabolic reactions.

Pharmacodynamics

Hydroxide ions can impact biological processes by changing the local pH, which influences enzyme activity, ion transport, and the solubility of other compounds. Their ability to neutralize acids can help regulate physiological pH, contributing to homeostasis in living organisms.

Pharmacokinetics

As an inorganic ion, hydroxide does not undergo traditional pharmacokinetic processes like absorption, distribution, metabolism, or excretion. Instead, it is rapidly equilibrated in biological fluids and participates in acid-base reactions, having immediate effects on the local environment.

Pregnancy

There is limited information regarding the use of hydroxide during pregnancy. Consult a healthcare professional for advice.

Breast-feeding

Limited data is available on the excretion of hydroxide in breast milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Fifth disease (erythema infectiosum)
• Anemia due to parvovirus B19 infection
• Complications in patients with hemolytic anemia

Dosage

Children: Dosage for treatment is not established, as parvovirus B19 infections are typically self-limiting. Supportive care is recommended.

Adults: Dosage for treatment is not established, as parvovirus B19 infections are typically self-limiting. Supportive care is recommended.

Mechanism of action

Parvovirus B19 primarily infects erythroid progenitor cells in the bone marrow, leading to cell lysis and a decrease in red blood cell production. This mechanism results in anemia, particularly in susceptible populations such as individuals with sickle cell disease or those undergoing chemotherapy. The virus uses the host cell's machinery for replication and can induce apoptosis in infected cells.

Pharmacodynamics

The pharmacodynamics of parvovirus B19 involve its interaction with host cellular receptors, notably the blood group P antigen, which facilitates viral entry into erythroid progenitor cells. The subsequent viral replication leads to cytopathic effects and an immune response that can exacerbate anemia and related symptoms. In immunocompetent individuals, the immune system typically resolves the infection without significant intervention.

Pharmacokinetics

Parvovirus B19 does not have a pharmacokinetic profile in the traditional sense, as it is a virus rather than a pharmaceutical agent. However, the viral replication cycle involves attachment to host cells, penetration, replication, and eventual release. The body's immune response plays a crucial role in controlling the infection, with antibodies appearing within 1-2 weeks of infection. Clearance of the virus generally occurs within 1-2 months.

Pregnancy

Parvo is not well studied in pregnant individuals. Caution is advised.

Breast-feeding

Limited data available, consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Pneumonia caused by multidrug-resistant gram-negative bacteria
• Septicemia caused by gram-negative bacteria
• Urinary tract infections caused by resistant organisms
• Skin infections caused by resistant gram-negative bacteria

Dosage

Children: Refer to BNF for Children for appropriate dosing in paediatric patients.

Adults: Refer to local guidelines or BNF for specific dosing recommendations based on the type and severity of infection.

Mechanism of action

Polymyxin exerts its antibacterial effect by disrupting the integrity of the bacterial cell membrane. It binds to the lipopolysaccharides and phospholipids in the outer membrane of gram-negative bacteria, leading to increased permeability and eventual cell lysis.

Pharmacodynamics

Polymyxin has a bactericidal effect against susceptible gram-negative organisms. Its action is concentration-dependent, with higher concentrations leading to a more significant bactericidal effect. Resistance can occur through modifications in the bacterial cell membrane components that reduce drug binding.

Pharmacokinetics

Polymyxin is poorly absorbed from the gastrointestinal tract and is typically administered parenterally (intravenously or intramuscularly) for systemic infections. It has a volume of distribution that suggests extensive tissue penetration but is primarily eliminated by the kidneys. Half-life varies based on renal function, and dose adjustments may be necessary in patients with renal impairment.

Adverse effects

• Nephrotoxicity
• Neurotoxicity
• Allergic reactions
• Respiratory distress
• Nausea
• Vomiting

Interactions

• Increased nephrotoxicity when used with other nephrotoxic agents such as aminoglycosides or cisplatin
• Potential for respiratory depression with neuromuscular blocking agents

Precautions

• Use with caution in patients with renal impairment
• Monitor renal function during therapy
• Consider the risk of neurotoxicity, especially with prolonged use

Pregnancy

Polymyxin is classified as category C. Its safety during pregnancy has not been established, thus it should only be used if clearly needed.

Breast-feeding

It is not known if polymyxin is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Protect from freezing.

Formulations

• Polymyxin B sulfate injection
• Polymyxin E (colistin) inhalation solution
• Topical formulations

Indications

• Assessment of immune status
• Monitoring vaccine efficacy
• Diagnosis of infections
• Determining need for booster vaccinations

Dosage

Children: Refer to specific guidelines or protocols for the context of use, as titre is a measurement rather than a drug requiring dosing.

Adults: Refer to specific guidelines or protocols for the context of use, as titre is a measurement rather than a drug requiring dosing.

Mechanism of action

The mechanism of action for titre is not applicable as it is a measurement rather than a drug. However, it reflects the immune response, which involves the binding of antibodies to specific antigens, leading to neutralization of pathogens or marking them for destruction by other immune cells.

Pharmacodynamics

Pharmacodynamics is not directly applicable to titre since it is a measurement of concentration rather than a pharmacological agent. However, the presence and concentration of antibodies can indicate the body's immune status and responsiveness to pathogens, with higher titres generally signifying a stronger immune response.

Pharmacokinetics

Pharmacokinetics is not relevant to titre measurements, as titre does not describe a substance that is metabolized or eliminated. Instead, it represents the stable concentration of antibodies in the serum following exposure to an antigen, whether through infection or vaccination.

Pregnancy

There is limited data on the safety of titre during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when using titre during breastfeeding. It is recommended to monitor the infant for any adverse effects.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Excessive dietary aluminum has been proposed to be a factor contributing to several neurological disorders in humans. Six 8-week-old female Swiss Webster mice were fed for 10 wk purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ug/g diet was higher (30%) than that in the 100 ug/g control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ug/g brain homogenates than in the 100 ug/g group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive substances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ug/g aluminum groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such as aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood-brain barrier, which regulates ex